This is a timely and essential companion to the recently published
Antimicrobial Resistance in the 21st Century, Second Edition. Antimicrobial resistance is a major threat to global population health, with government reports projecting it could result in over 10 million deaths in the next 35 years. Development of new agents to combat this threat is one of the WHO's top priorities, but in 2017, it conceded that the current drug development pipeline was insufficient to mitigate the threat. This book discusses recent progress and bolster new agent discovery and development, by providing researchers and students who will soon enter the field with a thorough guide to the advancements made in the last decade.
Coverage includes new systemic antimicrobials approved since 2010, with detailed analysis of antibiotics, antivirals, antifungals, and antiparasitics, as well as agents in development for future use. Discussion of each drug will include its chemical nature, pharmacology/pharmacokinetics, antimicrobial spectrum, dosage, adverse reactions, drug interactions, microbial resistance, indications, clinical efficacy compared to older agents, and lists of similar agents with cost comparison. This volume is designed for researchers and students of infectious disease and medical microbiology, as well as clinicians in need of a comprehensive guide to newly developed agents.
1. Antimicrobial Resistance: A crisis in the making.- 2: New
Cephalosporins: 5th and 6th generations.- 3: New -lactam--lactamase
inhibitor combinations.- 4: New Glycopeptides: Televancin, dalbavancin and
oritavancin.- 5: A new fluoroquinoloneDelafloxacin.- 6: New
Oxazolininone---Tedizolid.- 7: New Tetracyclines: Eravacycline and
Omadacycline.- 8: Pleuromutilin: A new class of antibiotic: Lefamulin.- 9:
New anti-tuberculous drugs: Bedaquiline, Delamanid and Pretomanid.- 10: New
systemic antifungal: Isavuconazole.- 11: Newly approved anti-parasitic drugs
for malaria, fascioliasis, onchocerciasis, Chagas disease and African
trypanosomiasis.- 12:New antiretroviral agents for HIV infection.- 13: New
Antiviral agents for cytomegalovirus diseases.- 14: New antiviral agent for
influenza: Baloxavir.- 15: Direct antiviral agents for hepatitis C.- 16:
Antiviral drugs for SARS-CoV-2 and COVID-19.- 17: New promising
antimicrobials in development and novel approaches for treatment of
infections.-
Ignatius Fong is the Editor of Springers Emerging Infectious Diseases of the 21st Century series. He has served as Chief Editor for six books and the sole author for another six books published in the series. He completed his residency training in Internal Medicine at the University of Toronto and as a Fellow in Infectious Diseases at the University of Washington, Seattle. Dr. Fong has published studies concerning a variety of infectious diseases that include therapeutics and pharmacology of antibiotics, AIDS and the treatment of opportunistic infections, mechanistic and treatment studies of mucosal candidiasis, and pathogenic studies on infection and induction of atherosclerosis in animal models. He was Chief of Infectious Diseases at St. Michaels Hospital (Toronto) for 34 years; he is still on staff in Infectious Diseases and is a Professor of Medicine, Department of Medicine at the University of Toronto, Canada.
Daugiau apie elektronines knygas